Analyst Reco. Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Real-time Estimate Cboe BZX Other stock markets 01:25:12 2024-05-17 pm EDT			5-day change	1st Jan Change
2.095 ^USD	-4.34%		+18.36%	-78.64%

May. 15	Pacific Biosciences, Ambry Genetics Selected to Sequence up to 7,000 Human Genomes	MT
May. 15	Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $4 From $10, Maintains Equal-Weight Rating	May. 15	MT
Piper Sandler Adjusts Price Target on Pacific Biosciences of California to $2 From $6.50, Maintains Neutral Rating	May. 13	MT
JPMorgan Downgrades Pacific Biosciences of California to Neutral From Overweight	Apr. 22	MT
Scotiabank Adjusts Pacific Biosciences of California's Price Target to $8 From $15, Maintains Sector Outperform Rating	Apr. 18	MT
Goldman Sachs Downgrades Pacific Biosciences of California to Neutral From Buy, Adjusts Price Target to $2.50 From $7	Apr. 18	MT
TD Cowen Adjusts Price Target on Pacific Biosciences of California to $2.50 From $12, Maintains Buy Rating	Apr. 17	MT
Goldman Sachs Cuts Price Target on Pacific Biosciences of California to $7 From $9, Maintains Buy Rating	Apr. 10	MT
UBS Trims Pacific Biosciences of California Price Target to $12 From $12.50, Maintains Buy Rating	Feb. 16	MT
UBS Lifts Price Target on Pacific Biosciences of California to $12.50 From $10, Keeps Buy Rating	Jan. 02	MT
Guggenheim Initiates Pacific Biosciences of California With Neutral Rating	Dec. 14	MT
UBS Upgrades Pacific Biosciences of California to Buy From Neutral, Cuts Price Target to $10 From $13	Nov. 17	MT
Piper Sandler Trims Price Target on Pacific Biosciences of California to $8 From $9, Maintains Neutral Rating	Nov. 06	MT
Cantor Fitzgerald Upgrades Pacific Biosciences of California to Overweight From Neutral, Cuts Price Target to $11 From $14	23-10-31	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $10 From $13, Maintains Equal-Weight Rating	23-10-24	MT
Barclays Cuts Price Target on Pacific Biosciences of California $9 From $14, Maintains Equalweight Rating	23-09-29	MT
Bernstein Starts Pacific Biosciences of California With Outperform Rating, $11 Price Target	23-09-28	MT
UBS Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Neutral Rating	23-08-04	MT
Morgan Stanley Adjusts Price Target on Pacific Biosciences of California to $13 From $12, Maintains Equalweight Rating	23-08-03	MT
Goldman Sachs Starts Pacific Biosciences of California at Buy With $17 Price Target	23-06-30	MT
Canaccord Genuity Adjusts Price Target on Pacific Biosciences of California to $17 From $14, Maintains Buy Rating	23-06-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Pacific Biosciences of California, Inc.

Equities

PACB

US69404D1081

Analyst Reco.

Filters